VALONTAN * BB 4CPR RIV 25MG
Prevention and treatment of nausea, vomiting and vertigo, typical of naupathias (seasickness, car, train, plane sickness).
Dosage and method of use
In children aged 2-6 years: 1 tablet or 1 suppository of VALONTAN children up to a maximum of 3 times a day, as needed. In children aged 7-12 years: 1-2 tablets or suppositories of VALONTAN children 2-3 times a day. It is recommended to take about 30 minutes before obtaining the desired effect. Do not administer to children under 2 years of age (see 4.3) Do not exceed the recommended dose. Do not use for prolonged treatments.
Hypersensitivity to the active substance or to any of the excipients. Contraindicated in children under 2 years of age. Generally contraindicated during pregnancy and lactation.
The most frequent side effect of antihistamines is sedation which can manifest as drowsiness. Dry mouth, photosensitivity, accommodation disorders, urination disorders, headache, anorexia, nausea, allergic skin reactions may occur with the use of antihistamines. Less frequently dizziness, asthenia, insomnia (especially in children), euphoria, tremors, hypotension, tachycardia and, at high doses, especially in children, convulsions.
The use of antihistamines at the same time as certain antibiotics or other ototoxic drugs can mask the early signs of ototoxicity, which can only reveal itself when the damage is irreversible. Use with caution in subjects suffering from glaucoma, prostatic hypertrophy, other urinary retention syndromes, intestinal obstruction, arterial hypertension, cardiovascular disease, bronchial asthma, chronic bronchitis or emphysema, hyperthyroidism. The medicine can exacerbate seizure disorders. It should therefore be used with great caution in subjects suffering from epilepsy. The tablets contain sucrose and are therefore not suitable for people with hereditary fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.
Pregnancy and breastfeeding
It is not recommended for use during pregnancy. In breastfeeding patients, it is necessary to decide whether to give up breastfeeding the baby and start the treatment or, vice versa, continue breastfeeding avoiding the administration of the product.
Expiry and retention
Interactions with other drugs
During the treatment, in order to prevent additive phenomena of sedation, it is necessary to avoid that the child is given drugs that act on the Central Nervous System.
Sleepiness is the most usual symptom of overdosing. Toxic doses can produce: convulsions, coma and respiratory depression. If necessary, implement symptomatic therapy; when necessary, respiratory assistance.
Coated tablets : Each coated tablet contains: Active ingredient Dimenhydrinate 25 mg Suppositories : Each suppository contains : Active ingredient Dimenhydrinate 25 mg For excipients: see 6.1
Coated tablets : Each coated tablet contains: Excipients: Sucrose 15.0 mg, polyvinylpyrrolidone 2.0 mg, precipitated silica 1.5 mg, magnesium stearate 1.5 mg, corn starch 45.0 mg, hydroxypropylmethylcellulose 1.875 mg, polyethylene glycol 400 0.1875 mg, titanium dioxide 0.9375 mg. Suppositories : Each suppository contains: Excipients: 10 mg precipitated silica, 1500 mg semisynthetic glycerides.